UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease

Annals of oncology, 2017-04, Vol.28 (4), p.727-732

2017

Volltextzugriff (PDF)

The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy

Annals of oncology, 2012-10, Vol.23 (10), p.2605-2612

2012

Volltextzugriff (PDF)

New treatments in ovarian cancer

Annals of oncology, 2017-11, Vol.28 (suppl_8), p.viii57-viii60

Pujade-Lauraine, E

2017

Volltextzugriff (PDF)

Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO

British journal of cancer, 2013-05, Vol.108 (9), p.1771-1777

2013

Volltextzugriff (PDF)

Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer

Annals of oncology, 2015-01, Vol.26 (1), p.120-125

2015

Volltextzugriff (PDF)

Recurrent ovarian cancer

Annals of oncology, 2016-04, Vol.27 Suppl 1 (suppl_1), p.i63-i65

2016

Volltextzugriff (PDF)

Mucinous advanced epithelial ovarian carcinoma: clinical presentation and sensitivity to platinum–paclitaxel-based chemotherapy, the GINECO experience

Annals of oncology, 2010-12, Vol.21 (12), p.2377-2381

2010

Volltextzugriff (PDF)

Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial

Annals of oncology, 2023-08, Vol.34 (8), p.681-692

2023

Volltextzugriff (PDF)

How to approach patients in relapse

Annals of oncology, 2012-09, Vol.23 Suppl 10, p.x128-x131

Pujade-Lauraine, E

2012

Volltextzugriff (PDF)

Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study

Annals of oncology, 2011-11, Vol.22 (11), p.2417-2423

2011

Volltextzugriff (PDF)

Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial

Annals of oncology, 2022-10, Vol.33 (10), p.1021-1028

2022

Volltextzugriff (PDF)

Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: A phase II GINECO trial

Gynecologic oncology, 2009-04, Vol.113 (1), p.16-20

2009

Volltextzugriff (PDF)

Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial

Annals of oncology, 2023-12, Vol.34 (12), p.1152-1164

2023

Volltextzugriff (PDF)

Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis

Annals of oncology, 2023-02, Vol.34 (2), p.152-162

2023

Volltextzugriff (PDF)

Development of a geriatric vulnerability score in elderly patients with advanced ovarian cancer treated with first-line carboplatin: a GINECO prospective trial

Annals of oncology, 2013-11, Vol.24 (11), p.2808-2813

2013

Volltextzugriff (PDF)

The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer

Annals of oncology, 2022-06, Vol.33 (6), p.593-601

2022

Volltextzugriff (PDF)

Update of randomized trials in recurrent disease

Annals of oncology, 2011-12, Vol.22 Suppl 8, p.viii61-viii64

2011

Volltextzugriff (PDF)

Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: Analysis of prospective randomised phase III trials

European journal of cancer (1990), 2013-01, Vol.49 (1), p.142-149

2013

Volltextzugriff (PDF)

Angiogenesis: A promising therapeutic target for ovarian cancer

Critical reviews in oncology/hematology, 2012-12, Vol.84 (3), p.314-326

2012

Volltextzugriff (PDF)

Should We Abandon Systematic Pelvic and Paraaortic Lymphadenectomy in Low-Grade Serous Ovarian Cancer?

Annals of surgical oncology, 2020-10, Vol.27 (10), p.3882-3890

2020

Volltextzugriff (PDF)

Integrating bevacizumab into the management of epithelial ovarian cancer: the controversy of front-line versus recurrent disease

Annals of oncology, 2013-12, Vol.24 Suppl 10, p.x53-x58

2013

Volltextzugriff (PDF)

Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial

Annals of oncology, 2017-08, Vol.28 (8), p.1842-1848

2017

Volltextzugriff (PDF)

Quality of life predicts overall survival in women with platinum-resistant ovarian cancer: an AURELIA substudy

Annals of oncology, 2017-08, Vol.28 (8), p.1849-1855

2017

Volltextzugriff (PDF)

Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens (GINECO)

Annals of oncology, 2012-02, Vol.23 (2), p.346-352

2012

Volltextzugriff (PDF)

1 – 25 von 323

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(310)
Mit Volltextzugriff
(276)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(129)
Life Sciences & Biomedicine
(117)
Science & Technology
(117)
Female
(111)
Oncology
(103)
Aged
(68)
Ovarian Neoplasms - Drug Therapy
(63)
Ovarian Cancer
(61)
Middle Aged
(59)
Biological And Medical Sciences
(56)
Medical Sciences
(55)
Adult
(52)
Tumors
(47)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(44)
Ovarian Neoplasms - Pathology
(38)
Gynecology. Andrology. Obstetrics
(34)
Pharmacology. Drug Treatments
(30)
Female Genital Diseases
(29)
Antineoplastic Agents
(27)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(26)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease

The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy

New treatments in ovarian cancer

Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO

Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer

Recurrent ovarian cancer

Mucinous advanced epithelial ovarian carcinoma: clinical presentation and sensitivity to platinum–paclitaxel-based chemotherapy, the GINECO experience

2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004)

Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial

How to approach patients in relapse

Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study

Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial

Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: A phase II GINECO trial

Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial

Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis

Development of a geriatric vulnerability score in elderly patients with advanced ovarian cancer treated with first-line carboplatin: a GINECO prospective trial

The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer

Update of randomized trials in recurrent disease

Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: Analysis of prospective randomised phase III trials

Angiogenesis: A promising therapeutic target for ovarian cancer

Should We Abandon Systematic Pelvic and Paraaortic Lymphadenectomy in Low-Grade Serous Ovarian Cancer?

Integrating bevacizumab into the management of epithelial ovarian cancer: the controversy of front-line versus recurrent disease

Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial

Quality of life predicts overall survival in women with platinum-resistant ovarian cancer: an AURELIA substudy

Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens (GINECO)

Suchergebnisse filtern